Investors
Aug 10, 2026
Taipei, Taiwan, 10 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for July 2026 of NT$2,492 million, representi...
.jpg)
ESG
Jul 29, 2026
Taipei, Taiwan and Seoul, South Korea, 29 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795, “Lotus” or the “Company”), a global pharmaceutical company headquartered in Taiwan, today announced that ...
Business
Jul 15, 2026
Taipei, Taiwan, 15 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that the United States Food and Drug Administration ("US FDA") has accepted for substantive re...
Business
Jul 15, 2026
Taipei, Taiwan, 15 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced the first hospital formulary listing and initial commercial shipment of Bostin...
Investors
Jul 13, 2026
Taipei, Taiwan, 13 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for June 2026 of NT$3,399 million, representing...
Business
Jul 7, 2026
Taipei, Taiwan, and Seoul, South Korea, 7 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that its wholly owned subsidiary Alvogen Korea has succ...
